Real-world genomic analysis highlights unmet
medical need in GU cancer patients with TSC1/2 inactivating
alterations
LOS
ANGELES, Jan. 26, 2024 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company
focused on developing and commercializing precision therapies for
patients with mTOR pathway alterations, today announced poster
presentations at the 2024 American Society of Clinical Oncology
(ASCO) Genitourinary Cancers Symposium, taking place January
25-27, 2024, in San Francisco, CA.
Abstract and poster presentation details are below:
Title: "Analysis of inactivating alterations in TSC1 and TSC2
in advanced genitourinary (GU) cancers from a real-world patient
population in the Foundation Medicine genomic
database"
Session Title: Poster Session B: Urothelial
Carcinoma
Date/Time: January 26, 2024 – 11:30 –
1:00 pm; 5:45 – 6:45 pm PST
Presenting Author: Gopa Iyer, MD
Key Findings:
- In a large real-world database of patients with advanced
cancer, 1,828 (4.0%) of the 46,068 patients with GU cancers had at
least one inactivating alteration in TSC1 or
TSC2
- TSC1 and/or TSC2 inactivating alterations were
present in 9.2% of patients with bladder cancer, 6.4% of patients
with kidney cancer, and 0.6% of patients with prostate cancer
- GU cancers with TSC1 and/or TSC2 inactivating
alterations were frequently microsatellite stable and of low tumor
mutational burden (TMB)
- The PRECISION 1 study (NCT05103358) is currently enrolling
patients with solid tumors harboring TSC1 and/or TSC2
inactivating alterations
Aadi is also presenting an encore Trials-in-Progress (TiP)
poster from the ongoing PRECISION 1 study.
Title: "PRECISION 1: A phase 2, multicenter,
open-label tumor-agnostic trial of nab-sirolimus for malignant
solid tumors harboring pathogenic inactivating
alterations in TSC1 and TSC2"
Session Title: Trials
in Progress Poster Session C: Renal Cell Cancer: Adrenal, Penile,
Urethral and Testicular Cancers
Date/Time: January 27, 2024 – 7:00 –
8:00 am; 11:30
am – 1:00 pm PST
Presenting Author: Gopa Iyer, MD
More information can be found on the ASCO GU meeting
website.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies for genetically defined cancers to bring
transformational therapies to cancer patients with mTOR pathway
driver alterations. Aadi received FDA approval and has
commercialized FYARRO® for the treatment of adult
patients with locally advanced unresectable or metastatic malignant
perivascular epithelioid cell tumor (PEComa).
Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic
registration-intended trial in mTOR inhibitor-naïve malignant solid
tumors harboring TSC1 or TSC2 inactivating
alterations. More information on the Company's development pipeline
is available on the Aadi website at www.aadibio.com and
connect with us on Twitter and LinkedIn.
Contact:
Marcy
Graham
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-announces-poster-presentations-at-the-2024-american-society-of-clinical-oncology-asco-genitourinary-gu-cancers-symposium-302045933.html
SOURCE Aadi Bioscience